Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vadas

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
NEJM Evidence|February 6, 2024
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
NEJM Evidence|February 6, 2024
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
Pageof 6